Bolt Biotherapeutics Reports 2024 Financial Results and Updates

Bolt Biotherapeutics, Inc. ( (BOLT) ) has released its Q4 earnings. Here is a breakdown of the information Bolt Biotherapeutics, Inc. presented to its investors.

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer treatment, leveraging its expertise in myeloid biology and cancer drug development. The company recently released its fourth quarter and full-year 2024 financial results, highlighting significant progress in its clinical programs and strategic collaborations. Key developments include the completion of enrollment for the Phase 1 trial of BDC-3042, a first-in-class dectin-2 agonist, and preparations for the clinical trial of BDC-4182, a next-generation ISAC targeting claudin 18.2, set to begin in the second quarter of 2025. Financially, Bolt Biotherapeutics reported a cash balance of $70.2 million, expected to support operations through mid-2026, despite a decrease in collaboration revenue and a net loss of $63.1 million for the year. The company continues to advance its collaborations with Genmab and Toray, aiming to develop next-generation cancer therapies. Looking ahead, Bolt Biotherapeutics remains focused on advancing its pipeline and achieving key clinical milestones, with a strategic emphasis on programs that could significantly impact patient outcomes.